GRWD0715 / GreyWolf Therapeutics - LARVOL DELTA

EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial - 1) (clinicaltrials.gov) - P1/2 | N=141 | Recruiting | Sponsor: Grey Wolf Therapeutics | Not yet recruiting ➔ Recruiting

Enrollment open • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Seronegative Spondyloarthropathies • Spondylarthritis

Greywolf Therapeutics begins dosing of the first treatment to target the antigenic source of autoimmunity (GlobeNewswire) - "Greywolf Therapeutics...have successfully dosed the first healthy volunteer in their Phase 1/2 trial (NCT07047703) evaluating GRWD0715, an oral ERAP1 inhibitor, for the treatment of axial spondyloarthritis (axSpA)."

Trial status • Spondylarthritis

EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial - 1) (clinicaltrials.gov) - P1/2 | N=141 | Not yet recruiting | Sponsor: Grey Wolf Therapeutics

New P1/2 trial • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Seronegative Spondyloarthropathies • Spondylarthritis

Therapeutic development for Axial Spondyloarthritis: ERAP-1 inhibition by GRWD0715 results in auto-antigen loss on HLA-B*27 and the inhibition of cognate CD8+ T cell responses. (FOCIS 2025) - "We present in silico analysis that implicatesGRWD0715-mediated loss of auto-antigen-HLA-B*27 resulted from the derivation of incompatible a.a. residues at the P2 anchor position. Together these data support the development of GRWD0715 as a disease-modifying therapy for axSpA and other HLA-B*27-associated autoimmune disease through the removal of HLA-I-presented autoantigens and the inhibition of auto-reactive CD8+ T cell responses."

Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Seronegative Spondyloarthropathies • CD8 • HELQ • HLA-B • SEC14L2

Therapeutic Development for Axial Spondyloarthritis: ERAP-1 Inhibition by GRWD0715 Results in Auto-Antigen Loss on HLA-B*27 and the Inhibition of Cognate CD8⁺ T Cell Responses (FOCIS 2025) - "We present in silico analysis that implicatesGRWD0715-mediated loss of auto-antigen-HLA-B*27 resulted from the derivation of incompatible a.a. residues at the P2 anchor position. Together these data support the development of GRWD0715 as a disease-modifying therapy for axSpA and other HLA-B*27-associated autoimmune disease through the removal of HLA-I-presented autoantigens and the inhibition of auto-reactive CD8+ T cell responses."

Late-breaking abstract • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Seronegative Spondyloarthropathies • CD8 • HELQ • HLA-B • SEC14L2

Grey Wolf Therapeutics Closes Oversubscribed $50 Million Series B Financing Expansion, Led by ICG Life Sciences Team, to Accelerate and Expand First-of-its-Kind Antigen Modulation Technology (PRNewswire) - "Grey Wolf Therapeutics...announced the closing of an oversubscribed $50 million Series B financing expansion, bringing the total amount of Series B funds raised to $99 million...Proceeds from the round will be leveraged to broaden the scope of the company's ongoing Phase 1/2 clinical trial of its lead immuno-oncology candidate, GRWD5769, in a range of solid tumour types. The funding also enables the company to expand research and development (R&D) for its versatile antigen modulation approach into treatments for autoimmune disease indications....Initial data on the ongoing adaptive Phase 1/2 trial of the lead asset GRWD5769, a first-in-class ERAP1 inhibitor will be presented at the upcoming 2024 American Society of Clinical Oncology (ASCO) annual meeting. A second ERAP1 inhibitor focussed on autoimmune disease is being advanced through IND-enabling studies with the goal of entering the clinic in 2025."

Financing • New trial • P1/2 data • Immunology • Oncology • Solid Tumor